Characterization of Innate immune receptors

先天免疫受体的表征

基本信息

  • 批准号:
    7451469
  • 负责人:
  • 金额:
    $ 25.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-09-15 至 2010-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Celiac disease (Cd) is a T cell mediated disease of the small intestine. It is triggered by dietary gluten proteins from cereals and affects 1 in 130 US citizens. While Cd can lead to severe malabsorption, most patients present with minor or atypical (nondiarrheal) symptoms. Cd is associated with secondary autoimmunity, such as type 1 diabetes or autoimmune thyroiditis, and longterm Cd that has not been treated with a strict gluten free diet can lead to (gastrointestinal) malignancy. Gluten peptides that have been deamidated by the Cd autoantigen tissue transglutaminase bind strongly to HLA-DQ2 or -DQ8, the essential genetic predisposition for Cd. This results in intestinal Th1 T cell activation and mucosal destruction (adaptive immunity). Apart from triggering adaptive immunity, recent data suggest that gluten (gliadin) can also stimulate innate immunity, i.e., the immediate and relatively nonspecific immune response to common foreign antigens, such as bacterial polysaccharide or viral RNA. The variable contribution of innate immunity to gliadin could explain why only 2- 5% of those individuals that carry HLA-DQ2 or -DQ8 finally develop Cd. The responsible gliadin peptide(s) and the receptors mediating innate immunity to gluten remain to be identified. Our preliminary results show that a peptic-tryptic digest of gliadin which contains roughly 1000 different gliadin peptides triggers a marked innate immune response in human dendritic but also intestinal epithelial cells, as assessed by release of the inflammatory mediators interleukin 8 and MCP-1. Based on these data we plan to: 1. Identify the gliadin peptide(s) that drive innate immunity after their chromatographic separation by using dendritic (intestinal epithelial) as indicators and MALDI-TOF mass spectrometry. 2. Isolate and characterize the innate immune receptor(s) on these cells that trigger(s) the innate immune response to gliadin by use of affinity chromatography of labeled cell membranes on the identified immobilized stimulatory gliadin peptide(s) and MALDI-TOF mass spectrometry. Identity and function of the receptor(s) will further be confirmed by use of function blocking antibodies, siRNA and signaling pathway inhibitors. We anticipate that identification of the receptor(s) responsible for the innate immune response to gliadin will lead to a better understanding of the pathogenesis of Cd, and possibly to novel nondietary therapies to treat this common intestinal disorder. PUBLIC HEALTH RELEVANCE Celiac disease (Cd) is a common immune disease of the small intestine that affects 1 in 130 US citizens. It is triggered by ingestion of the storage proteins of wheat (glutenins and especially gliadins) and related cereals. Cd that is not treated by strict dietary gluten exclusion can lead to severe malabsorption and malignancy, and is associated with secondary autoimmunity, such as type 1 diabetes. While the adaptive (T cell mediated) immune response to gluten peptides that leads to destruction of the resorptive intestinal mucosa is well understood, there is a yet ill defined innate immune response (the immediate and relatively nonspecific reaction to foreign antigens, such as bacterial polysaccharide or viral RNA) to gliadins. The responsible gliadin peptide(s) and the receptors mediating innate immunity to gluten remain to be identified. We plan to identify the gliadin peptide(s) that drive innate immunity in human dendritic and intestinal epithelial cells and characterize their responsive innate immune receptor(s) by use of proteomic techniques, affinity chromatography and functional studies. We anticipate that identification of the receptor(s) responsible for the innate immune response to gliadin will lead to a better understanding of the pathogenesis of Cd, and possibly to novel nondietary therapies to treat this common intestinal disorder.
描述(由申请人提供):乳糜泻(Cd)是一种T细胞介导的小肠疾病。它是由谷物中的膳食面筋蛋白引发的,每130名美国公民中就有1人受到影响。虽然镉可导致严重的吸收不良,但大多数患者表现为轻微或非典型(非消化性)症状。镉与继发性自身免疫有关,如1型糖尿病或自身免疫性甲状腺炎,长期镉没有得到严格的无麸质饮食治疗可能导致(胃肠道)恶性肿瘤。已脱酰胺的镉自身抗原组织转氨酶谷蛋白肽强烈结合HLA-DQ 2或-DQ 8,镉的基本遗传易感性。这导致肠道Th 1 T细胞活化和粘膜破坏(适应性免疫)。除了引发适应性免疫外,最近的数据表明谷蛋白(麦胶蛋白)还可以刺激先天免疫,即,对常见外来抗原(如细菌多糖或病毒RNA)的直接和相对非特异性免疫反应。先天免疫对麦醇溶蛋白的可变贡献可以解释为什么携带HLA-DQ 2或-DQ 8的个体中只有2- 5%最终发展为Cd。负责的麦胶蛋白肽和介导对麸质的先天免疫的受体仍有待鉴定。 我们的初步研究结果表明,麦胶蛋白,其中包含大约1000种不同的麦胶蛋白肽的肽-胰蛋白酶消化触发了显着的先天性免疫反应,在人类树突状细胞,但也肠上皮细胞,评估释放的炎症介质白细胞介素8和MCP-1。基于这些数据,我们计划:1。通过使用树突状细胞(肠上皮细胞)作为指示剂和MALDI-TOF质谱法进行色谱分离后,鉴定驱动先天免疫的麦胶蛋白肽。2.通过使用已识别的固定刺激性麦醇溶蛋白肽上的标记细胞膜的亲和层析和MALDI-TOF质谱法,分离并表征这些细胞上触发对麦醇溶蛋白的先天免疫反应的先天免疫受体。受体的身份和功能将通过使用功能阻断抗体、siRNA和信号传导途径抑制剂进一步确认。 我们预计,识别的受体(S)负责的先天免疫反应麦醇溶蛋白将导致更好地了解镉的发病机制,并可能以新的非饮食疗法来治疗这种常见的肠道疾病。 乳糜泻(Cd)是一种常见的小肠免疫性疾病,每130名美国公民中就有1名受到影响。它是由小麦和相关谷物的储藏蛋白(麦谷蛋白,特别是麦醇溶蛋白)的摄入引发的。镉如果不通过严格的饮食麸质排除来治疗,会导致严重的吸收不良和恶性肿瘤,并与继发性自身免疫有关,如1型糖尿病。虽然对谷蛋白肽的适应性(T细胞介导的)免疫应答导致再吸收肠粘膜的破坏是很好理解的,但对麦胶蛋白的先天性免疫应答(对外来抗原如细菌多糖或病毒RNA的直接且相对非特异性的反应)还不清楚。负责的麦胶蛋白肽和介导对麸质的先天免疫的受体仍有待鉴定。我们计划通过使用蛋白质组学技术、亲和层析和功能研究来鉴定在人树突细胞和肠上皮细胞中驱动先天免疫的麦胶蛋白肽,并表征其应答性先天免疫受体。我们预计,识别的受体(S)负责的先天免疫反应麦醇溶蛋白将导致更好地了解镉的发病机制,并可能以新的非饮食疗法来治疗这种常见的肠道疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DETLEF SCHUPPAN其他文献

DETLEF SCHUPPAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DETLEF SCHUPPAN', 18)}}的其他基金

Fibrolytic Activation of Hepatic Stellate Cells by T Cell Derived Microparticles
T 细胞衍生微粒对肝星状细胞的纤维溶解激活
  • 批准号:
    7386870
  • 财政年份:
    2009
  • 资助金额:
    $ 25.5万
  • 项目类别:
Viral, T Cell, and Cytokine Determinants of Hepatic Stellate Cell Activation
肝星状细胞激活的病毒、T 细胞和细胞因子决定因素
  • 批准号:
    7575790
  • 财政年份:
    2008
  • 资助金额:
    $ 25.5万
  • 项目类别:
Characterization of Innate immune receptors
先天免疫受体的表征
  • 批准号:
    7686836
  • 财政年份:
    2008
  • 资助金额:
    $ 25.5万
  • 项目类别:
Identification of Serum Markers of Liver Fibrogenesis/ Fibrolysis by Proteomics
通过蛋白质组学鉴定肝纤维发生/纤维溶解的血清标志物
  • 批准号:
    7313389
  • 财政年份:
    2007
  • 资助金额:
    $ 25.5万
  • 项目类别:
Identification of Serum Markers of Liver Fibrogenesis/ Fibrolysis by Proteomics
通过蛋白质组学鉴定肝纤维发生/纤维溶解的血清标志物
  • 批准号:
    7493091
  • 财政年份:
    2007
  • 资助金额:
    $ 25.5万
  • 项目类别:
Mouse Models for Celiac Disease
乳糜泻小鼠模型
  • 批准号:
    7017340
  • 财政年份:
    2006
  • 资助金额:
    $ 25.5万
  • 项目类别:
Mouse Models for Celiac Disease
乳糜泻小鼠模型
  • 批准号:
    7229848
  • 财政年份:
    2006
  • 资助金额:
    $ 25.5万
  • 项目类别:
Viral, T Cell, & Cytokine Determinants of Stellate Cell
病毒、T 细胞、
  • 批准号:
    7013913
  • 财政年份:
    2005
  • 资助金额:
    $ 25.5万
  • 项目类别:
Determinants of Liver Injury in Chronic Hepatitis C Virus Infection
慢性丙型肝炎病毒感染肝损伤的决定因素
  • 批准号:
    7575792
  • 财政年份:
    2005
  • 资助金额:
    $ 25.5万
  • 项目类别:
Determinants of Liver Injury in Chronic Hepatitis C Virus Infection
慢性丙型肝炎病毒感染肝损伤的决定因素
  • 批准号:
    7385107
  • 财政年份:
    2005
  • 资助金额:
    $ 25.5万
  • 项目类别:

相似海外基金

Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
  • 批准号:
    10506915
  • 财政年份:
    2021
  • 资助金额:
    $ 25.5万
  • 项目类别:
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
  • 批准号:
    10325006
  • 财政年份:
    2021
  • 资助金额:
    $ 25.5万
  • 项目类别:
SBIR Phase I: A New Class of Immobilized Metal Affinity Chromatography Resins
SBIR 第一阶段:一类新型固定金属亲和色谱树脂
  • 批准号:
    1746198
  • 财政年份:
    2018
  • 资助金额:
    $ 25.5万
  • 项目类别:
    Standard Grant
Marine speciation of nickel using immobilized nickel affinity chromatography
使用固定镍亲和色谱法测定镍的海洋形态
  • 批准号:
    512537-2017
  • 财政年份:
    2017
  • 资助金额:
    $ 25.5万
  • 项目类别:
    University Undergraduate Student Research Awards
I-Corps: Commercialization of Immobilized Metal Affinity Chromatography Resins Based on Nanomaterials
I-Corps:基于纳米材料的固定化金属亲和层析树脂的商业化
  • 批准号:
    1404605
  • 财政年份:
    2014
  • 资助金额:
    $ 25.5万
  • 项目类别:
    Standard Grant
Antibody Purification via Affinity Chromatography that Utilizes the Unconventional Nucleotide Binding Site
利用非常规核苷酸结合位点通过亲和色谱法纯化抗体
  • 批准号:
    1263713
  • 财政年份:
    2013
  • 资助金额:
    $ 25.5万
  • 项目类别:
    Continuing Grant
Development of multivalent DNA network based affinity chromatography diagnostics for isolating circulating tumour cells
开发基于多价 DNA 网络的亲和色谱诊断法,用于分离循环肿瘤细胞
  • 批准号:
    425749-2012
  • 财政年份:
    2012
  • 资助金额:
    $ 25.5万
  • 项目类别:
    Postgraduate Scholarships - Master's
Next-Generation Affinity Chromatography with PEGylated Ligands
使用聚乙二醇化配体的新一代亲和色谱法
  • 批准号:
    1159886
  • 财政年份:
    2012
  • 资助金额:
    $ 25.5万
  • 项目类别:
    Standard Grant
Immobilized zirconium ion affinity chromatography for specific enrichment of phosphoproteins
用于磷蛋白特异性富集的固定化锆离子亲和层析
  • 批准号:
    19560760
  • 财政年份:
    2007
  • 资助金额:
    $ 25.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accelerating drug discovery using frontal affinity chromatography/mass spectrometry
使用正面亲和色谱/质谱加速药物发现
  • 批准号:
    234753-2000
  • 财政年份:
    2003
  • 资助金额:
    $ 25.5万
  • 项目类别:
    Collaborative Research and Development Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了